期刊
VIRUSES-BASEL
卷 11, 期 1, 页码 -出版社
MDPI
DOI: 10.3390/v11010030
关键词
HCV; DAA; antiviral targets
类别
资金
- French Agence Nationale de la Recherche sur le SIDA et les Hepatites Virales (ANRS)
- European Research Council [ERC-2008-AdG-233130-HEPCENT]
- LabEx Ecofect of the Universite de Lyon, within the program Investissements d'Avenir [ANR-11-LABX-0048, ANR-11-IDEX-0007]
Hepatitis C infection is the leading cause of liver diseases worldwide and a major health concern that affects an estimated 3% of the global population. Novel therapies available since 2014 and 2017 are very efficient and the WHO considers HCV eradication possible by the year 2030. These treatments are based on the so-called direct acting antivirals (DAAs) that have been developed through research efforts by academia and industry since the 1990s. After a brief overview of the HCV life cycle, we describe here the functions of the different targets of current DAAs, the mode of action of these DAAs and potential future inhibitors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据